$AYTU

$1.90 -$0.03 (1.55%) Live

$AYTU Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 10.9M shares outstanding

Who owns AYTU?

By type of holder

Institutions 100.0% Insiders 0.0% Everyone else 0.0%

Concentration Top 10 holders own 380.4%

BlackRock, Inc. 85.0% · Encompass Capital Advisors LLC 60.4%

Institutional ownership

100.0%

0 pts vs last qtr

Institutional holders

196

+5 vs last qtr

Net shares bought

+806.2K

by institutions in Q2 2026

New / sold out

39 / 34

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

BlackRock, Inc. +889.1K
Marshall Wace, LLP NEW +835.7K

Biggest sellers in Q2 2026

Susquehanna International Group, LLP SOLD OUT −1.1M
Jane Street Group, LLC −663.4K

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Aytu Biopharma Inc in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2021–FY2023

+298.9%

+99.72% a year

Each share's claim on the business

−74.9%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $14.9M

over 3 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years29% 1–3 years48% Under 1 year23%

Quarterly turnover

12.9%

of institutional shares changed hands

Top 10 managers, median time held

2.5 years

Super Investors

Investment managers reporting AYTU on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
B BlackRock, Inc.	9.2M	85.03%	+889.1K (+10.6%)	2023	0.0%
Shares held by quarter Peak holding9.2M (Q2'26) Change over 8 quarters+6.5M Share of the company85.030% BlackRock, Inc.'s full portfolio →
EC Encompass Capital Advisors LLC	6.6M	60.38%	−350.3K (−5.1%)	Q1 '26	1.5%
Shares held by quarter Peak holding6.9M (Q1'26) Change over 8 quarters+6.6M Share of the company60.380% Encompass Capital Advisors LLC's full portfolio →

BlackRock, Inc.

9.2M

% of company

85.03%

Change vs last qtr

+889.1K (+10.6%)

Held since

2023

Encompass Capital Advisors LLC

6.6M

% of company

60.38%

Change vs last qtr

−350.3K (−5.1%)

Held since

Q1 '26

28 more super investors behind a free account

See every manager holding Aytu Biopharma Inc, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting AYTU on Form N-PORT; together they hold 181.9% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$22.7M	3.8M	34.63%	0.00%	June 30, 2026
IR iShares Russell 2000 ETF iShares Trust	$18.9M	3.0M	27.99%	0.02%	June 30, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$22.7M

% of company

34.63%

% of the fund

0.00%

As of

June 30, 2026

iShares Russell 2000 ETF

iShares Trust

Position value

$18.9M

% of company

27.99%

% of the fund

0.02%

As of

June 30, 2026

23 more funds behind a free account

See every fund holding Aytu Biopharma Inc and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
MD Mack Daniel 5%+ holder 13D · 14.4%	1.1M	10.00%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company10.000% Disclosed stake13D · 14.4% View the 13D/G filing →
HW Harkey Wilmot B. 5%+ holder 13D · 14.4%	1.1M	10.00%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company10.000% Disclosed stake13D · 14.4% View the 13D/G filing →

Mack Daniel

5%+ holder13D · 14.4%

1.1M

% of company

10.00%

Change vs last qtr

—

Held since

—

Harkey Wilmot B.

5%+ holder13D · 14.4%

1.1M

% of company

10.00%

Change vs last qtr

—

Held since

—

8 more holders behind a free account

See every insider and 5%+ holder of Aytu Biopharma Inc.

Comments